JAGSNPHARM (JAGSNPHARM) Fair Value & Analysis
Healthcare · Market cap ₹15.5B
Fair value as of: Jul 3, 2026
From 26 valuation models · updated today
Share price +16.7% over the past month.
Price vs Fair Value (12 months)
12‑month range ₹161.56 – ₹285.09 · fair‑value band ₹81.44 – ₹154.65 · the ₹235.05 price screens above the ₹123.78 fair value. As of Jul 3, 2026.
✦ Which stocks are undervalued right now? Check free Discover now →Analysis
JAGSNPHARM (JAGSNPHARM) currently trades at ₹235.05, while our model-based Fair Value estimate is ₹123.78 — implying the stock looks roughly 47.3% overvalued today. We read business quality at 62/100 (solid quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: high).
Over the trailing twelve months, JAGSNPHARM generated revenue of ₹2.9B at a net margin of 15.0%. Revenue grew 9.6% year over year. It earns a return on equity of 16.7%. The balance sheet holds a net cash position of ₹18.8M. Fundamentals as of Jul 3, 2026
Key figures & financial health
More key figures
Figures from reported company fundamentals (EODHD) · as of Jul 3, 2026. TTM = trailing twelve months.
Revenue & earnings trend
FY2022 – FY2026 · reported fiscal years
JAGSNPHARM reported revenue of ₹2.9B in FY2026 versus ₹2.2B in FY2022, a compound +7.2%/yr. Reported net income was ₹431M in FY2026, compounding +22.9%/yr from FY2022.
Is JAGSNPHARM fairly valued? → Check now
Similar stocks
6 more Drug Manufacturers - Specialty & Generic stocks, each showing price versus our Fair Value estimate (as of Jul 3, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| 1276 1276 | HK$57.85 | HK$29.84 | -48% |
| Jiangsu Hengrui Pharmaceuticals Co 600276 | ¥47.08 | ¥26.59 | -44% |
| Sun Pharmaceutical Industries Limited SUNPHARMA | ₹1,786 | ₹991.46 | -44% |
| Zoetis Inc Z1TS34 | R$26.19 | R$26.01 | -1% |
| Hansoh Pharmaceutical Group 3692 | HK$29.30 | HK$23.90 | -18% |
| Divi's Laboratories Limited DIVISLAB | ₹6,639 | ₹1,281 | -81% |
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is JAGSNPHARM (JAGSNPHARM) undervalued?
What is the fair value of JAGSNPHARM?
What is the quality score of JAGSNPHARM?
What is the revenue of JAGSNPHARM (JAGSNPHARM)?
What is the net profit margin of JAGSNPHARM?
Does JAGSNPHARM pay a dividend?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.